Glycogen Synthase Kinase-3 as Drug Target: From Wallflower to Center of Attention

Drug News and Perspectives

Volumn 16, Issue 9, 2003, Pages 557-565

  Van Wauwe, Jean ^a,b   Haefner, Burkhard ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Janssen Pharmaceutica ^*  (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINO 1,2,5 OXADIAZOLYL) 1,2,3 TRIAZOLE DERIVATIVE; 1H IMIDAZOL 4 AMINE; 1H PYRAZOL 3 AMINE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 2 AMINOPYRAZINE DERIVATIVE; 2 PYRIDINYLIMIDAZO[1,2 A]PYRIMIDONE DERIVATIVE; 2 PYRIDINYLPYRIMIDO[1,2 A]PYRIMIDONE DERIVATIVE; 2,4 DIAMINOTHIAZOLE DERIVATIVE; 4 THIAZOLYLPYRIMIDIN 2 AMINE DERIVATIVE; 4,5 DIHYDRO 1H PYRAZOL 5 ONE DERIVATIVE; ALSTERPAULLONE; AMINOPYRIMIDINE DERIVATIVE; CT 98023; CT 9803; CYCLIN DEPENDENT KINASE INHIBITOR; DIAZEPINE DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; HYMENIALDISINE; INDIRUBIN; LITHIUM SALT; PAULLONE DERIVATIVE; PHOSPHOPEPTIDE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDINE DERIVATIVE; SB 495052; SB 517995; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CELL CYCLE; CELL SURVIVAL; CYTOSKELETON; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; GLUCOSE METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIGNAL TRANSDUCTION;

ALZHEIMER DISEASE; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ENZYME INHIBITORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INFLAMMATION; PHOSPHORYLATION;

EID: 0347088944     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2003.16.9.829337     Document Type: Review

References (76)

1. Cohen, P. Protein kinases - The major drug targets of the twenty-first century? Nature Rev Drug Dis 2001, 1: 309-15.
2. Hunter, T. Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling. Cell 1995, 80: 225-36.
3. Johnson, L.N. and Lewis, R.J. Structural basis for control by phosphorylation. Chem Rev 2001, 101: 2209-42.
4. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. The protein kinase complement of the human genome. Science 2002, 298: 1912-34.
5. Frame, S. and Cohen, P. GSK3 takes center stage more than 20 years after its discovery. Biochem J 2001, 359: 1-16.
6. Doble, B.W. and Woodgett, J.R. GSK-3: Tricks of the trade for a multi-tasking kinase. J Cell Sci 2003, 116: 1175-86.
7. Woodgett, J.R. Judging a protein by more than its name: GSK-3. Science's STKE 2001, 100: RE12.
8. Ali, A., Hoeflich, P.K. and Woodgett, J.R. Glycogen synthase kinase-3: Properties, functions and regulation. Chem Rev 2001, 101: 2527-40.
9. Cohen, P. and Frame, S. The renaissance of GSK3. Nat Rev Mol Cell Biol 2001, 2: 769-76.
10. Liu, C., Li, Y., Semenov, M. et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002, 108: 837-47.
11. Dajani, R., Fraser, E., Roe, S.M. et al. Crystal structure of glycogen synthase kinase 3beta: Structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001, 105: 721-32.
12. Ter Haar, E., Coll, J., Austen, D.A., Hsiao, H.M., Swenson, L. and Jain, J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 2001, 8: 593-6.
13. Woodgett, J.R. Molecular cloning and expression of glycogen synthase kinase 3. EMBO J 1990, 9: 2431-8.
14. Hoeflich, K.P., Luo, J., Rubie, E.A., Tsao, M.S., Jin, O. and Woodgett, J. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 2000, 406: 86-90.
15. Phiel, C.J., Wilson, C.A., Lee, V.M.-Y. and Klein, P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423: 435-9.
16. Mukai, F., Ishiguro, K., Sano, Y. and Fujita, S.C. Alternative splicing isoform of tau protein 1/glycogen synthase kinase 3beta. J Neurochem 2002, 81: 1073-83.
17. Cross, D.A., Alessi, D.R., Cohen, P. Andjelkovich, M. and Hemmings, B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378: 785-9.
18. Frame, S., Cohen, P. and Biondi, R.M. A common phosphate binding group explains the unique substrate specificity of GSK-3 and its inactivation by phosphorylation. Mol Cell 2001, 7: 1321-7.
19. Fang, X., Yu, S.X., Lu, Y., Bast, R.C., Jr., Woodgett, J.R. and Mills, G.B. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci 2000, 97: 11960-5.
20. Sutherland, C. and Cohen, P. The alpha-isoform of glycogen synthase kinase-3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase activated protein kinase-1 in vitro. FEBS Lett 1994, 338: 37-42.
21. Gomperts, B.D., Tatham, P.E.R. and Kramer, I.M. Signal Transduction. Academic Press 2002: 192-7.
22. Cantley, L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296: 1655-7.
23. Fang, X., Yu, S., Tanyi, J.L., Lu, Y., Woodgett, J.R. and Mills G.B. Convergence of multiple signalling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 2002, 22: 2099-110.
24. Li, M., Wang, X., Meintzer, M.K., Laessig, T., Birnbaum, M.J. and Heidenreich, K.A. Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3beta. Mol Cell Biol 2000, 20: 9356-63.
25. Welsh, G.I., Miller, C.M., Loughlin, A.J., Price, N.T. and Proud, C.G. Regulation of eukaryotic initiation factor elF2B: Glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 1998, 421: 125-30.
26. Miller, J.R. The Wnts. Genome Biol 2002, 3: REVIEWS 3001.
27. Cadigan, K. and Nusse, R. Wnt signalling: A common theme in animal development. Genes Dev 1997, 11: 3286-305.
28. Hino, S., Michiue, T., Asashima, M. and Kikuchi, A. Casein kinase 1 enhances the binding of Dvl-1 to Frat-1 and is essential for Wnt-3a-induced accumulation of beta-catenin. J Biol Chem 2003, 278: 14066-73
29. Idar-Finkelman, H. Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol Med 2002, 8: 126-32.
30. Martinez, A., Castro, A., Dorronsoro, I. and Alonso, M. Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002, 22: 373-84.
31. Grimes, C.A. and Jope, R.S. The multifaceted role of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65: 391-426.
32. Kaidanovich, O. and Eldar-Finkelman, H. The role of glycogen synthase kinase-3 in insulin resistance and type 2 diabetes. Expert Opin Ther Targets 2002, 6: 555-61.
33. Eldar-Finkelman, H. and Krebs, E.G. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci USA 1997, 94: 9660-4.
34. Hardy, J. and Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002, 297: 353-6.
35. Lau, L.-F., Schachter, J.B., Seymour, P.A. and Sanner, M.A. Tau protein phosphorylation as a therapeutic target in Alzheimer's disease. Curr Top Med Chem 2002, 2: 395-415.
36. Ishiguro, K., Shiratsuchi, A., Sato, S. et al. Glycogen synthase kinase 3beta is identical to tau protein kinase generating several epitopes of paired helical filaments. FEBS Lett 1993, 325: 167-72.
37. Neal, J.W. and Clipstone, N.A. Glycogen synthase kinase-3 inhibits the DNA binding activity of NF-ATc. J Biol Chem 2001, 276: 3666-73.
38. Meng, F., Liu, L. Chin, P.C. and D'Mello, S.R. Akt is a downstream target of NF-kappaB. J Biol Chem 2002, 277: 29674-80.
39. Deng, J., Miller S.A., Wang H.-H. et al. Beat-catenin interacts with and inhibits NF-kappaB in human colon and breast cancer. Cancer Cell 2002, 2: 323-34.
40. Ryves, W.J. and Harwood, A.J. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001, 280: 720-5.
41. Phiel, C.J. and Klein, P.S. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001, 41: 789-813.
42. Williams, R.S., Cheng, L., Mudge, A.W. and Harwood, A.J. A common mechanism of action for three mood-stabilizing drugs. Nature 2002, 417: 292-5.
43. Thomas, G.M., Frame, S., Goedert, M., Nathke, I., Polakis, P. and Cohen, P.A. GSK-3-binding peptide from FRAT1 selectively inhibits the GSK-3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett 1999, 458: 247-51.
44. Martinez, A., Alonso, M. Castro, A., Perez, C. and Moreno, F.J. First non-ATP competitive glycogen synthase kinase-3beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002, 45: 1292-9.
45. Devos, R., Guisez, Y., Plaetinck, G. et al. Covalent modification of the interleukin-5 receptor by isothiazolones leads to inhibition of the binding of interleukin-5. Eur J Biochem 1994, 225: 635-40.
46. Hoessel, R., Leclerc, S., Endcott, J.A., Nobel, M.E.N. and Lawrie, A. Indirubin, the active constituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999,1: 60-7.
47. Leclerc, S., Garnier, M., Hoessel, R. et al. Indirubins inhibit glycogen synthase kinase-3beta and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzhei-mer's disease. J Biol Chem 2001, 276: 251-60.
48. Schultz, C., Link, A., Leost, M. et al. The paullones, a series of cyclin-dependent kinase inhibitory: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity. J Med Chem 1999, 42: 2909-19.
49. Leost, M., Schultz, C., Link, A. et al. Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25. Eur J Biochem 2000, 267: 5983-94.
50. Meijer, L., Thunnissen, A.-M.W.H., White, A.W. et al. Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 2000, 7: 51-63.
51. Hers, I. Tavare, J.M. and Denton, R.M. The protein kinase C inhibitors bisindolylmaleimide 1 (GF-109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett 1999, 460: 433-6.
52. Coghlan, M.P., Culbert, A.A., Cross, D.A et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 2000, 7: 793-803.
53. Cross, D.A.E., Culbert, A.A., Chambers, K.A., Facci, L., Skaper, S.D. and Reith, A.D. Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurons from death. J Neurochem 2001, 77: 94-102.
54. Norman, P. Emerging fundamental themes in modern medicinal chemistry. Drug News Perspect 2001, 14: 242-7.
55. Gong, L., Grupe, A. and Peltz, G.A. 3-Indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta. US Pat Appl US 2002/052397.
56. Prudhomme, M., Marminon, C., Moreau, P. et al. Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing same. World Pat Appl WO 03/035663.
57. Rawlings, D.A. and Witherington, J. Pyrazolo[3,4-C] pyridines as GSK-3 inhibitors. World Pat Appl WO 02/050073.
58. Smith, D.G. and Ward, R.W. Diamino-1,2,4-triazole-carboxylic and derivatives as GSK-3 inhibitors. World Pat Appl WO 01/009106.
59. Harris, P.A. and Wang, T.Y. Inhibitors of glycogen synthase kinase-3. World Pat Appl WO 03/024447.
60. Saady, M., Yaiche, P., Lochead, A. and Marguerie, S. 1-(Alkyl), 1-((heteroaryl)alkyl) and 1-(arylalkyl)-7-pyridin-4-ylimidazo-(1,2a)pyrimidin-5(1H)-one derivatives. World Pat Appl WO 02/018385.
61. Li, A.T., Nedelec, A., Gallet, T. et al. 2-Pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives. World Pat Appl WO 02/018386.
62. Sanner, M.A., Wager, T.T., Coper, C.B. and Helal, C.J. Pyrazone derivatives and their use as protein kinase inhibitors. World Pat Appl WO 02/018346.
63. Ahlijanian, M.K., Sanner, M.A., Villalobos, A. et al. Imidazole derivatives. World Pat Appl WO 02/10141.
64. Jingrong, C., Choquette, D., Davies, R. et al. 9-Deazaguanine derivatives as inhibitors of GSK-3. World Pat Appl WO 02/085909.
65. Cochran, J., Nanthakumar, J., Harrigton, E. and Wang, J. Thiazole derivatives useful as inhibitors of protein kinases. World Pat Appl WO 02/096905
66. Moon, Y.C., Green, J., Davies, R., Choquette, D., Pierce, A. and Ledeboer, M. 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors. World Pat Appl WO 02/102800.
67. Green, J., Arnost, M.J. and Pierce, A. Pyrazolon derivatives as inhibitors of GSK-3. World Pat Appl WO 03/011287.
68. Bowler, A.N., Kilburn, J.P., Engelhardt, S., Danielsen, G.M. and Kurthals, P. Novel substituted oxadiazepines with glucose lowering properties [Abst]. 16th Int Sym Med Chem 2000.
69. Olesen, P., Kurtzhals, P., Worsaee, H., Hansen, B.F., Soerensen, A.R. and Bowler, A.N. Furazanyl-triazole derivatives for the treatment of diseases. World Pat Appl WO 02/032896.
70. Soerensen, A.R., Worsaae, H., Hansen, B.F., Kurtzhals, P., Bowler, A.N. and Olesen, P.H. 2,4-Diaminothiazole derivatives and their use as glycogen synthase kinase-3 (GSK-3) inhibitors. World Pat Appl WO 01/056567, 2001.
71. Bowler, A.N. and Hansen, B.F. Novel 2.4-diaminothiazole derivatives. World Pat Appl WO 03/011843.
72. Nuss, J. and Zhou, X. Bicyclic inhibitors of glycogen synthase kinase 3. World Pat Appl WO 01/044246, 2001.
73. Savithri, R. and Nuss, J. Pyrazine based inhibitors of glycogen synthase kinase 3. World Pat Appl WO 01/044206, 2001.
74. Ramurthy, S., Desai, M., Nuss, J.M., Boyce, et al. World Pat Appl WO 02/020495, 2002.
75. Ramurthy, S., Goff, D., Nuss, J.M. et al. Inhibitors of glycogen synthase kinase 3. World Pat Appl WO 99/065897, 1999.
76. Samuels, I., Low, C., Fawcett, K. et al. Diabetes 2001, 50(Suppl 2) A325.